

## Administration Statements

### Approved Administration Statements

#### *For products with actuator*

FOR INTRANASAL USE WITH [PROPRIETARY NAME]  
NASAL ACTUATOR ONLY

FOR ORAL INHALATION WITH [PROPRIETARY NAME]  
ACTUATOR ONLY

#### *For inhalation or nasal spray products*

FOR ORAL INHALATION ONLY

FOR INTRANASAL USE ONLY

### Design Guidelines for Administration Statements

**Font family** Helvetica Neue Std.

**Font weight** Light Condensed.

#### **Font size**

9–12 point suggested. Panel size dependent.

#### **Relational size**

Font size should be 120% the size of the NDC number.

#### **Font tracking**

For statements that appear in all capital letters, increase tracking as follows: QuarkXPress setting at +6; Illustrator and InDesign settings at +30.

#### **Placement**

Principal display panel, beneath Strength/Metered Dose Statement.

Spacing from baseline of Strength/Metered Dose Statement to baseline of Administration Statement should be 250% of font size, or adjusted as necessary to achieve an equal amount of white space above and below the Strength/Metered Dose Statement.

*Alignment:* Left aligned.

#### **Margins**

Margins from the seal area to any foil pouch panel must be a minimum of 1/8" (3 mm; 9 points).

#### **Color**

*Light background color or foil:* Black.

*Dark background color:* Reverse to white. Font weight should change to Medium.

*Preferred background color:* Foil pouch background prints white.

#### **Reference**

21 CFR Section 201.5. Drugs; adequate directions for use.